Aileen Rubio, PhD, is the Head of Biology for Spero Therapeutics in Cambridge, MA. She previously held positions of increasing responsibility at Cubist Pharmaceuticals, where she worked for over 9 years. During that time, she worked on antibacterial discovery projects, as well as provided support for business development activities. She has also collaborated with several key opinion leaders to investigate the mechanism of action/resistance of Cubicin (daptomycin for injection) in Staphylococcus aureus.
Dr. Rubio received BS degrees in both Microbiology and Chemistry from the University of Illinois at Champaign-Urbana, a PhD in Bacteriology from the University of Wisconsin at Madison and completed post-doctoral research at the University of California at San Diego.
Michael Lewinski, Ph.D., D(ABMM), CM, MB(ASCP)CM is currently the Sr. Director of Medical Affairs, Microbiology and Smarticles technology at Roche Molecular Systems, Inc. in Pleasanton, California. He completed his Doctor of Philosophy degree in Microbiology and Immunology and a clinical postdoctoral Fellowship in Medical and Public Health Laboratory Microbiology at UCLA. He is a Diplomate of the American Board of Medical Microbiology, a licensed Laboratory Director and a certified Molecular Biologist. Prior to joining Roche, he was the Chief of Microbiology and Associate Clinical Professor of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA. Prior to UCLA he was the Senior Scientific Director of Infectious Diseases at Quest Diagnostics Nichols Institute and Focus Diagnostics, Inc. He has served as the President of the Southern California Branch of the American Society for Microbiology, on the Council of the Pan American Society of Clinical Virology and as Chair of the Infectious Disease Subdivision of the Association for Molecular Pathology and he currently serves on the Membership/Nominations Committee of the Pan American Society for Clinical Virology and the Editorial Board of the Journal of Clinical Virology. His research interests have focused on the development and the automation of molecular tests for the detection, quantification, and characterization of microorganisms for the diagnosis of disease and for monitoring disease progression and response to therapy. He holds several patents and has published in various disciplines within infectious diseases and laboratory medicine.
Greg Bleck is Global Head of Research and Development at Catalent Biologics with overall responsibility for development and acquisition of new products and technologies. Greg was an original employee of Gala Biotech (acquired by Catalent), where he used his knowledge of gene expression and transgenic systems to develop and optimize retrovector expression systems and the proprietary GPEx® process. Prior to joining Gala, Greg performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and expression. He holds a B.S. and a Ph.D. in Endocrinology-Reproductive Physiology, both from the University of Wisconsin-Madison. Greg has published over 60 research papers, co-authored three book chapters, and is an inventor or co-inventor on eight issued patents and eight patents currently under review.